The finding that the prevalence of the KRAS-variant is significantly higher in women tested within two years of ovarian cancer diagnosis likely reflects the fact that these patients have worse ovarian cancer specific survival and a higher risk for interim death over time [14]. Here, KRAS is linked to ovarian cancer.